Venom

Hennessey Celebrates ‘World’s Fastest Car’ Accolade with 300mph Plans

Retrieved on: 
Tuesday, February 20, 2024

SEALY, Texas, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Hennessey Special Vehicles, the Texas-based hypercar manufacturer, has set out plans for its 1,817bhp Venom F5 to exceed 300mph in 2024. The announcement was timed to coincide with the 10th anniversary of the company’s Venom GT becoming the world’s fastest car in February 2014.

Key Points: 
  • 2014 - World's Fastest Car: 270.49 mph Hennessey Venom GT
    SEALY, Texas, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Hennessey Special Vehicles, the Texas-based hypercar manufacturer, has set out plans for its 1,817bhp Venom F5 to exceed 300mph in 2024.
  • The announcement was timed to coincide with the 10th anniversary of the company’s Venom GT becoming the world’s fastest car in February 2014.
  • 2024 marks the tenth anniversary of the Hennessey Venom GT achieving a verified world record 270.49mph top speed to become the fastest production car ever.
  • Prospective clients may inquire by calling the Hennessey Special Vehicles sales team at +1 979.885.1300 or visiting HennesseySpecialVehicles.com .

Draft guideline on allergen products development for immunotherapy and allergy diagnosis in moderate to low-sized study populations

Retrieved on: 
Tuesday, March 12, 2024

16

Key Points: 
    • 16

      Guideline on allergen products development for
      immunotherapy and allergy diagnosis in moderate to lowsized study populations

      17

      Table of contents

      18

      Executive summary ..................................................................................... 3

      19

      1.

    • Specific effects ................................................................................................. 17

      14
      15

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 2/18

      53

      12.

    • Management for allergies may involve avoidance of the allergen, medications to relieve

      66

      symptoms, or allergen immunotherapy (AIT) to desensitize the immune system to the allergen.

    • 71

      Recommendations are made on the clinical development, potential study designs and safety

      72

      considerations for allergen products within the scope of the guideline.

    • Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 3/18

      88

      While allergen specific immunotherapy is the only known disease modifying therapy for type I allergies,

      89

      there is no such treatment available for type IV allergies.

    • 93

      Several guidelines applicable for allergen products are available (see section 3) and provide advice on

      94

      quality and clinical development according to the current knowledge.

    • Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 4/18

      127

      However, this guideline does not cover the indication of atopic dermatitis or asthma as these

      128

      conditions will require separate clinical trials (see Section 6).

    • 129

      In addition, the guideline does not cover medicinal allergen products manufactured using recombinant

      130

      DNA technology, synthetic peptides, DNA or RNA constructs and/or cell preparations as they differ

      131

      substantially to the allergen products as discussed above.

    • 1

      156

      ?

      Guideline on the clinical development of products for specific immunotherapy for the treatment

      157
      158

      of allergic diseases - CHMP/EWP/18504/2006
      ?

      159
      160
      161

      Guideline on Allergen Products: Production and Quality Issues EMEA/CHMP/BWP/304831/2007

      ?

      Guideline on process validation for finished products - information and data to be provided in
      regulatory submissions - EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev1, Corr.1

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 5/18

      162

      ?

      Recommendations on common regulatory approaches for allergen products - CMDh/399/2019

      163

      4.

    • In any

      199

      case, a reduced validation should include all relevant manufacturing process steps that are considered
      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 6/18

      200

      product specific.

    • 290

      Diagnostic allergen products (Type I allergy)

      291

      A possible target indication is diagnosis of type I hypersensitivity (immediate-type allergy) by prick,

      292

      intracutaneous or provocation testing.

    • 298

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 9/18

      305
      306

      7.1.

    • Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 11/18

      377

      8.

    • Clinical development of products for AIT: Study design,
      efficacy and safety

      378

      In general, the clinical development should be performed according to current guidelines.

    • In such single trial, the suitability as a test allergen as well as the

      376

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 12/18

      415

      dose finding for the therapeutic allergen could be investigated.

    • Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 13/18

      454
      455

      8.2.1.

    • 493

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 15/18

      527

      In general, sensitivity and specificity of the product should be determined.

    • 540

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 16/18

      561

      10.2.

    • Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 17/18

      595

      4.

    • Allergol Immunopathol, 1989;

      602

      17(2):53-65

      603

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 18/18

Beast Tourney Runs Sunday, February 25th, awarding 30 Seats to Record-Setting $12.5 Million Venom

Retrieved on: 
Monday, February 19, 2024

SAN JOSE, Costa Rica, Feb. 19, 2024 /PRNewswire/ -- The record-setting $12.5 Million Venom tournament is coming to ACR Poker this April and the popular poker site is awarding tons of seats through their Venom Fever promotion.

Key Points: 
  • SAN JOSE, Costa Rica, Feb. 19, 2024 /PRNewswire/ -- The record-setting $12.5 Million Venom tournament is coming to ACR Poker this April and the popular poker site is awarding tons of seats through their Venom Fever promotion.
  • "Our $12.5 Million Venom is our biggest tournament ever and a true milestone in the online poker industry," stated ACR Pro Chris Moneymaker.
  • ACR Poker is offering lots of ways for players to get their $12.5 Million Venom seat for pennies on the dollar.
  • Moneymaker also added that the Venom will crown at least two millionaires, plus many other players will win life-changing scores.

ACR Poker Offers Dozens of Tickets to $12.5 Million Venom at Enjoy Poker Series in Uruguay

Retrieved on: 
Friday, February 16, 2024

SAN JOSE, Costa Rica, Feb. 16, 2024 /PRNewswire/ -- ACR Poker today announced additional opportunities for poker players to win their seat to the massive $12.5 Million GTD Venom tournament coming this April. Players can qualify for ACR Poker's biggest tourney ever during the Enjoy Poker Series in Uruguay. 

Key Points: 
  • Players can qualify for ACR Poker's biggest tourney ever during the Enjoy Poker Series in Uruguay.
  • Taking place from February 16th-24th, the Enjoy Poker Series returns to beautiful Punta del Este with eight days of tournament action for all bankrolls.
  • Participants can compete for Main Event and Mega Satellite tickets to the $12.5 Million Venom, which takes place from April 14th to May 1st.
  • "It's great to see these additional avenues for players to qualify for the $12.5 Million Venom," said ACR Pro Chris Moneymaker.

'Berodualn' Wins More Than $544,000 in ACR Poker's Latest Venom PKO

Retrieved on: 
Friday, February 2, 2024

SAN JOSE, Costa Rica, Feb. 2, 2024 /PRNewswire/ -- After days of intense competition in the Venom PKO, 'berodualn' has been crowned champion of ACR Poker's massive progressive knockout tournament.

Key Points: 
  • SAN JOSE, Costa Rica, Feb. 2, 2024 /PRNewswire/ -- After days of intense competition in the Venom PKO, 'berodualn' has been crowned champion of ACR Poker's massive progressive knockout tournament.
  • 'berodualn' from Austria took home the coveted Venom PKO title and a total payout of $544,875, following a strong performance at the final table.
  • The champion eliminated 'niceoneee' in the flagship event, winning a life-changing prize of $416,787 and a staggering $128,088 in bounties.
  • Commenting on his deep run in the Venom PKO, ACR Pro Drew Gonzalez said, "Having another deep run in the Venom for me was super fun!

ACR Poker Making New Year's Resolutions Come True with $5 Million Venom PKO

Retrieved on: 
Friday, January 12, 2024

The popular worldwide poker site is returning its $5 Million GTD Venom PKO tourney starting Thursday, January 18th.

Key Points: 
  • The popular worldwide poker site is returning its $5 Million GTD Venom PKO tourney starting Thursday, January 18th.
  • "Our Venom PKO is well known as the biggest Progressive Knockout tourney in online poker," stated ACR Pro Chris Moneymaker.
  • In the Venom PKO, players take part in some of the biggest hands of their life with single bounties worth tens of thousands of dollars.
  • The $5 Million Venom PKO costs $2,650 to get into, but players can qualify for far less via Venom Fever.

Introducing the All-New Venom BlackBook Zero 14 Phantom: Where Unmatched Performance Meets True Sustainability for High Performance Business Computing

Retrieved on: 
Tuesday, November 21, 2023

MELBOURNE, Australia, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Venom is thrilled to unveil the next evolution in our high-performance laptop range: the BlackBook Zero 14 Phantom Gen 9.

Key Points: 
  • MELBOURNE, Australia, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Venom is thrilled to unveil the next evolution in our high-performance laptop range: the BlackBook Zero 14 Phantom Gen 9.
  • Packed with cutting-edge features and built with sustainability in mind, this is our most powerful, versatile, and eco-friendly BlackBook to date.
  • The unibody chassis, coated in signature Imperial Graphite Black, exudes a minimalist and timeless elegance.
  • We firmly believe that the new BlackBook Zero 14 Phantom sets a new standard in the ultraportable segment, with no compromise on speed, user experience, or sustainability.

Venom Computers Unveils BlackBook Zero 14 Phantom G9: Intelligent Performance Meets Sustainability

Retrieved on: 
Wednesday, November 15, 2023

MELBOURNE, Australia, Nov. 15, 2023 /PRNewswire/ -- In a major leap forward for high-performance computing, Venom Computers announced the launch of its newest model: the BlackBook Zero 14" Phantom G9. The Phantom G9 is the latest example of Venom's commitment to blending unmatched power with conscientious sustainability and is designed for Venom's exclusive users, who include discerning professionals and informed tech enthusiasts.

Key Points: 
  • Flawlessly designed and engineered for the ultraportable laptop niche, Venom continues to redefine high performance eco-friendly tech
    MELBOURNE, Australia, Nov. 15, 2023 /PRNewswire/ -- In a major leap forward for high-performance computing, Venom Computers announced the launch of its newest model: the BlackBook Zero 14" Phantom G9.
  • "The Zero 14 Phantom isn't just about leading-edge specs, though we're proud of those," said Jaan Turon, Director of Venom.
  • Blackbook Zero 14 Phantom G9: Performance Beyond Boundaries
    Boasting a 13th Gen Intel Core i7-1360p processor, the Zero 14 Phantom G9 achieves up to a 40% real-world speed increment over previous models.
  • Go online to learn more about the new Blackbook Zero 14 Phantom G9, Intelligent Performance, and the Venom Value Cycle.

Hennessey's ‘Venom 775’ F-150 Stings Factory TRX and Raptor R

Retrieved on: 
Tuesday, October 24, 2023

SEALY, Texas, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Hennessey, the Texas-based hypercar manufacturer and high-performance vehicle creator, reintroduces its updated Venom 775 – a Ford F-150-based pickup fitted with a supercharged V8 that offers more horsepower and torque than the factory RAM TRX and Ford Raptor R.

Key Points: 
  • The fuel injectors and fuel system are upgraded, and a high-flow air induction system is installed.
  • A stainless-steel cat-back exhaust is mounted to reduce back pressure and improve the exhaust note.
  • Performance is stunning, as the 0-60 sprint takes a mere 3.6 seconds, with the quarter mile falling in just 11.9 seconds.
  • John Hennessey, company founder and CEO: "The Venom 775 is the ultimate sleeper pickup truck, with more than enough power to embarrass stock TRX and Raptor R owners.

Marvel’s Spider-Man 2 Breaks Sales Records to Become Fastest-selling PlayStation Studios Game in PlayStation History

Retrieved on: 
Monday, October 23, 2023

Today, Sony Interactive Entertainment announced that Marvel’s Spider-Man 2, developed by Insomniac Games in collaboration with PlayStation Studios and Marvel Games, has sold more than 2.5 million copies to become the fastest-selling PlayStation Studios game in PlayStation history in the first 24 hours.

Key Points: 
  • Today, Sony Interactive Entertainment announced that Marvel’s Spider-Man 2, developed by Insomniac Games in collaboration with PlayStation Studios and Marvel Games, has sold more than 2.5 million copies to become the fastest-selling PlayStation Studios game in PlayStation history in the first 24 hours.
  • View the full release here: https://www.businesswire.com/news/home/20231023019066/en/
    Marvel's Spider-Man 2 Breaks Sales Records to Become Fastest-selling PlayStation Studios Game in PlayStation History (Graphic: Sony Interactive Entertainment)
    “Insomniac Games holds itself to incredibly high standards when it comes to delivering engaging and innovative gameplay experiences,” said Eric Lempel, SVP, Global Marketing, Sales, and Business Operations, Sony Interactive Entertainment.
  • “Marvel’s Spider-Man 2 is Insomniac Games’ third installment in the franchise for PlayStation.
  • *Includes pre-order sales of individual units and units bundled with PlayStation 5.